<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39587352</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-1534</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature reviews. Microbiology</Title><ISOAbbreviation>Nat Rev Microbiol</ISOAbbreviation></Journal><ArticleTitle>The consequences of SARS-CoV-2 within-host persistence.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41579-024-01125-y</ELocationID><Abstract><AbstractText>SARS-CoV-2 causes an acute respiratory tract infection that resolves in most people in less than a month. Yet some people with severely weakened immune systems fail to clear the virus, leading to persistent infections with high viral titres in the respiratory tract. In a subset of cases, persistent SARS-CoV-2 replication results in an accelerated accumulation of adaptive mutations that confer escape from neutralizing antibodies and enhance cellular infection. This may lead to the evolution of extensively mutated SARS-CoV-2 variants and introduce an element of chance into the timing of variant evolution, as variant formation may depend on evolution in a single person. Whether long COVID is also caused by persistence&#xa0;of replicating SARS-CoV-2 is controversial. One line of evidence is detection of SARS-CoV-2 RNA and proteins in different body compartments long after SARS-CoV-2 infection has cleared from the upper respiratory tract. However, thus far, no replication competent virus has been cultured from individuals with&#xa0;long COVID&#xa0;who are immunocompetent. In this Review, we consider mechanisms of viral persistence, intra-host evolution in persistent infections, the connection of persistent infections with SARS-CoV-2 variants and the possible role of SARS-CoV-2 persistence in long COVID. Understanding persistent infections may therefore resolve much of what is still unclear in COVID-19 pathophysiology, with possible implications for other emerging viruses.</AbstractText><CopyrightInformation>&#xa9; 2024. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sigal</LastName><ForeName>Alex</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8571-2004</Identifier><AffiliationInfo><Affiliation>The Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. alexander.sigal@mail.huji.ac.il.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Africa Health Research Institute, Durban, South Africa. alexander.sigal@mail.huji.ac.il.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. alexander.sigal@mail.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neher</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-2525-1407</Identifier><AffiliationInfo><Affiliation>Biozentrum, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swiss Institute of Bioinformatics, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lessells</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0003-0926-710X</Identifier><AffiliationInfo><Affiliation>KwaZulu-Natal Research Innovation &amp; Sequencing Platform, School of Laboratory Medicine &amp; Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Microbiol</MedlineTA><NlmUniqueID>101190261</NlmUniqueID><ISSNLinking>1740-1526</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: A.S. has received an honorarium from Pfizer for consultation and has active grants on COVID-19 from the Bill and Melinda Gates Foundation and The Wellcome Trust. R.A.N is a paid consultant for Moderna and BioNtech, and has active grants on COVID-19 from the&#xa0;Swiss National Science Foundation and the Swiss Federal Office for Public Health. R.J.L declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39587352</ArticleId><ArticleId IdType="doi">10.1038/s41579-024-01125-y</ArticleId><ArticleId IdType="pii">10.1038/s41579-024-01125-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. WHO COVID19 dashboard. WHO https://data.who.int/dashboards/covid19/ (2024).</Citation></Reference><Reference><Citation>Ao, D., He, X., Liu, J. &amp; Xu, L. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. Signal. Transduct. Target. Ther. 8, 466 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38129394</ArticleId><ArticleId IdType="pmc">10739883</ArticleId><ArticleId IdType="doi">10.1038/s41392-023-01724-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, B. S. Rapid COVID-19 vaccine development. Science 368, 945&#x2013;946 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32385100</ArticleId><ArticleId IdType="doi">10.1126/science.abb8923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadfield J. et al. Genomic epidemiology of SARS-CoV-2 with subsampling focused globally since pandemic start. Nextstrain https://nextstrain.org/ncov/gisaid/global/all-time (2024).</Citation></Reference><Reference><Citation>Sigal, A., Milo, R. &amp; Jassat, W. Estimating disease severity of Omicron and Delta SARS-CoV-2 infections. Nat. Rev. Immunol. 22, 267&#x2013;269 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35414124</ArticleId><ArticleId IdType="pmc">9002222</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00720-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigal, A. Milder disease with Omicron: is it the virus or the pre-existing immunity? Nat. Rev. Immunol. 22, 69&#x2013;71 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35046570</ArticleId><ArticleId IdType="pmc">8767774</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00678-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Telenti, A. et al. After the pandemic: perspectives on the future trajectory of COVID-19. Nature 596, 495&#x2013;504 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34237771</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03792-w</ArticleId></ArticleIdList></Reference><Reference><Citation>UKHSA. UKHSA dashboard. GOV.UK https://ukhsa-dashboard.data.gov.uk/ (2024).</Citation></Reference><Reference><Citation>World Health Organization. COVID-19 epidemiological update &#x2013; 17 June 2024. WHO https://www.who.int/publications/m/item/covid-19-epidemiological-update-edition-168 (2024).</Citation></Reference><Reference><Citation>Ke, R. et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat. Microbiol. 7, 640&#x2013;652 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35484231</ArticleId><ArticleId IdType="pmc">9084242</ArticleId><ArticleId IdType="doi">10.1038/s41564-022-01105-z</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465&#x2013;469 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32235945</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach, O., Meyer, B. &amp; Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. Nat. Rev. Microbiol. 21, 147&#x2013;161 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36460930</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim, F. et al. Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation. Nat. Commun. 15, 2360 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38491050</ArticleId><ArticleId IdType="pmc">10943233</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-46673-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Machkovech, H. M. et al. Persistent SARS-CoV-2 infection: significance and implications. Lancet Infect. Dis. 24, e453&#x2013;e462 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38340735</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00815-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly, Z. et al. Long COVID science, research and policy. Nat. Med. 30, 2148&#x2013;2164 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39122965</ArticleId><ArticleId IdType="doi">10.1038/s41591-024-03173-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai, M., Xie, Y., Topol, E. J. &amp; Al-Aly, Z. Three-year outcomes of post-acute sequelae of COVID-19. Nat. Med. 30, 1564&#x2013;1573 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38816608</ArticleId><ArticleId IdType="pmc">11186764</ArticleId><ArticleId IdType="doi">10.1038/s41591-024-02987-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele, S. et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe 30, 154&#x2013;162.e5 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35120605</ArticleId><ArticleId IdType="pmc">8758318</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2022.01.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cleemput, J. et al. Organ-specific genome diversity of replication-competent SARS-CoV-2. Nat. Commun. 12, 6612 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34785663</ArticleId><ArticleId IdType="pmc">8595628</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-26884-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Nkosi, T. et al. Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. eLife 11, e78374 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35880744</ArticleId><ArticleId IdType="pmc">9355563</ArticleId><ArticleId IdType="doi">10.7554/eLife.78374</ArticleId></ArticleIdList></Reference><Reference><Citation>Raglow, Z. et al. SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the Omicron period: a multicentre, prospective analysis. Lancet Microbe 5, e235&#x2013;e246 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38286131</ArticleId><ArticleId IdType="doi">10.1016/S2666-5247(23)00336-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, D. S. W., Rojas, O. L. &amp; Gommerman, J. L. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat. Rev. Drug. Discov. 20, 179&#x2013;199 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33324003</ArticleId><ArticleId IdType="doi">10.1038/s41573-020-00092-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan, A. et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med 3, 371&#x2013;387.e9 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35434682</ArticleId><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639&#x2013;644 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33461210</ArticleId><ArticleId IdType="pmc">8221082</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal, A. D. et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat. Immunol. 24, 1616&#x2013;1627 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37667052</ArticleId><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kampen, J. J. A. et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat. Commun. 12, 267 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33431879</ArticleId><ArticleId IdType="pmc">7801729</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-20568-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner, A. et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology 163, 495&#x2013;506.e8 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35508284</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Avanzato, V. A. et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 183, 1901&#x2013;1912.e9 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33248470</ArticleId><ArticleId IdType="pmc">7640888</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.10.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Baang, J. H. et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J. Infect. Dis. 223, 23&#x2013;27 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33089317</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiaa666</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazykin, G. A. et al. Emergence of Y453F and &#x394;69&#x2013;70HV mutations in a lymphoma patient with long-term COVID-19. Virological https://virological.org/t/emergence-of-y453f-and-69-70hv-mutations-in-a-lymphoma-patient-with-long-term-covid-19/580 (2021).</Citation></Reference><Reference><Citation>Borges, V. et al. Long-term evolution of SARS-CoV-2 in an immunocompromised patient with non-hodgkin Lymphoma. mSphere 6, e0024421 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34319130</ArticleId><ArticleId IdType="doi">10.1128/mSphere.00244-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaguza, C. et al. Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection. Cell Rep. Med. 4, 100943 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36791724</ArticleId><ArticleId IdType="pmc">9906997</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2023.100943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, L. et al. Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment. mSphere 6, e0048021 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34431691</ArticleId><ArticleId IdType="doi">10.1128/mSphere.00480-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, B. et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N. Engl. J. Med. 383, 2291&#x2013;2293 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33176080</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2031364</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Abramo, A. et al. B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience. Front. Med. 11, 1344267 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1344267</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Reiche, A. S. et al. Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants. Nat. Commun. 14, 3235 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37270625</ArticleId><ArticleId IdType="pmc">10239218</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-38867-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277&#x2013;282 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33545711</ArticleId><ArticleId IdType="pmc">7610568</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig, G. et al. SARS-CoV-2 infection in immunosuppression evolves sub-lineages which independently accumulate neutralization escape mutations. Virus Evol. 10, vead075 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38361824</ArticleId><ArticleId IdType="doi">10.1093/ve/vead075</ArticleId></ArticleIdList></Reference><Reference><Citation>Maponga, T. G. et al. Persistent severe acute respiratory syndrome coronavirus 2 infection with accumulation of mutations in a patient with poorly controlled human immunodeficiency virus infection. Clin. Infect. Dis. 76, e522&#x2013;e525 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35793242</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac548</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruki, T. et al. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma. J. Infect. Chemother. 30, 793&#x2013;795 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38242284</ArticleId><ArticleId IdType="doi">10.1016/j.jiac.2024.01.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiring, S. et al. Prolonged shedding of SARS-CoV-2 at high viral loads amongst hospitalised immunocompromised persons living with HIV, South Africa. Clin. Infect. Dis. 75, e144&#x2013;e156 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35134129</ArticleId><ArticleId IdType="pmc">8903337</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogimi, C. et al. Prolonged shedding of human coronavirus in hematopoietic cell transplant recipients: risk factors and viral genome evolution. J. Infect. Dis. 216, 203&#x2013;209 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28838146</ArticleId><ArticleId IdType="doi">10.1093/infdis/jix264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarhini, H. et al. Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection. J. Infect. Dis. 223, 1522&#x2013;1527 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33556961</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiab075</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatamzas, E. et al. Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection. Nat. Commun. 13, 5586 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36151076</ArticleId><ArticleId IdType="pmc">9508331</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-32772-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanevich, O. V. et al. SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19. Nat. Commun. 14, 149 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36627290</ArticleId><ArticleId IdType="pmc">9831376</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-34033-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinori, A. &amp; Bausch-Jurken, M. The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future. J. Infect. Dis. 228, S4&#x2013;S12 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37539764</ArticleId><ArticleId IdType="pmc">10401620</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad181</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinori, A. et al. Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T-lymphocyte count. Clin. Infect. Dis. 75, e552&#x2013;e563 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35366316</ArticleId><ArticleId IdType="pmc">9047161</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuano, K. S., Seth, N. &amp; Chinen, J. Secondary immunodeficiencies: an overview. Ann. Allergy Asthma Immunol. 127, 617&#x2013;626 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34481993</ArticleId><ArticleId IdType="doi">10.1016/j.anai.2021.08.413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasingham, R. et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect. Dis. 22, 1748&#x2013;1755 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36049486</ArticleId><ArticleId IdType="pmc">9701154</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00499-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinson, M. L. &amp; Lapham, J. Prevalence of immunosuppression among US adults. JAMA 331, 880&#x2013;882 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38358771</ArticleId><ArticleId IdType="pmc">10870224</ArticleId><ArticleId IdType="doi">10.1001/jama.2023.28019</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans, R. A. et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg. Health Eur. 35, 100747 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38115964</ArticleId><ArticleId IdType="pmc">10730312</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2023.100747</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. et al. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci. Transl. Med. 16, eadk1599 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38266109</ArticleId><ArticleId IdType="pmc">10982957</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.adk1599</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepasse, P. R. et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br. J. Haematol. 190, 185&#x2013;188 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32557623</ArticleId><ArticleId IdType="pmc">7300950</ArticleId><ArticleId IdType="doi">10.1111/bjh.16896</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Abramo, A. et al. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach. Int. J. Infect. Dis. 107, 247&#x2013;250 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33901654</ArticleId><ArticleId IdType="pmc">8065233</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2021.04.068</ArticleId></ArticleIdList></Reference><Reference><Citation>Fax&#xe9;n, L. &amp; Edvinsson, M. Persistent SARS-CoV-2 infection in patients with B-cell deficiency: a case series of successful antiviral treatment of four patients. Ups J. Med. Sci. 128, https://doi.org/10.48101/ujms.v128.9807 (2023).</Citation></Reference><Reference><Citation>Hueso, T. et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood 136, 2290&#x2013;2295 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32959052</ArticleId><ArticleId IdType="doi">10.1182/blood.2020008423</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabascall, C. X., Lou, B. X., Navetta-Modrov, B. &amp; Hahn, S. S. Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab. BMJ Case Rep. 14, e243469 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34344651</ArticleId><ArticleId IdType="pmc">8336168</ArticleId><ArticleId IdType="doi">10.1136/bcr-2021-243469</ArticleId></ArticleIdList></Reference><Reference><Citation>Totschnig, D., Doberer, D., Haberl, R., Wenisch, C. &amp; Valipour, A. Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody sotrovimab. IDCases 29, e01528 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35694274</ArticleId><ArticleId IdType="pmc">9172259</ArticleId><ArticleId IdType="doi">10.1016/j.idcr.2022.e01528</ArticleId></ArticleIdList></Reference><Reference><Citation>HIV and AIDS Estimates South Africa 2021. UNAIDS https://www.unaids.org/en/regionscountries/countries/southafrica (2022).</Citation></Reference><Reference><Citation>World Health Organization. People living with HIV globally in 2023. WHO https://www.who.int/data/gho/data/themes/hiv-aids (2023).</Citation></Reference><Reference><Citation>Chihana, M. L. et al. Distribution of advanced HIV disease from three high HIV prevalence settings in sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South Africa), Ndhiwa (Kenya) and Chiradzulu (Malawi). Glob. Health Action. 12, 1679472 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31679482</ArticleId><ArticleId IdType="pmc">6844432</ArticleId><ArticleId IdType="doi">10.1080/16549716.2019.1679472</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona, S. et al. Persistent high burden of advanced HIV disease among patients seeking care in South Africa&#x2019;s National HIV program: data from a nationwide laboratory cohort. Clin. Infect. Dis. 66, S111&#x2013;S117 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29514238</ArticleId><ArticleId IdType="pmc">5850436</ArticleId><ArticleId IdType="doi">10.1093/cid/ciy045</ArticleId></ArticleIdList></Reference><Reference><Citation>Stelzle, D. et al. High prevalence of advanced HIV disease in sub-Saharan Africa: an analysis of 11 household surveys. Top. Antivir. Med. 32, 196 (2024).</Citation></Reference><Reference><Citation>Maloney, D. G. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 366, 2008&#x2013;2016 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22621628</ArticleId><ArticleId IdType="doi">10.1056/NEJMct1114348</ArticleId></ArticleIdList></Reference><Reference><Citation>de S&#xe8;ze, J. et al. Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front. Immunol. 14, 1004795 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37033984</ArticleId><ArticleId IdType="pmc">10076836</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1004795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly, S., Nedosekin, D. &amp; Wong, H. K. Review of an anti-CD20 monoclonal antibody for the treatment of autoimmune diseases of the skin. Am. J. Clin. Dermatol. 24, 247&#x2013;273 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36630066</ArticleId><ArticleId IdType="pmc">9838371</ArticleId><ArticleId IdType="doi">10.1007/s40257-022-00751-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Boye, J., Elter, T. &amp; Engert, A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14, 520&#x2013;535 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12649096</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdg175</ArticleId></ArticleIdList></Reference><Reference><Citation>Boross, P. &amp; Leusen, J. H. Mechanisms of action of CD20 antibodies. Am. J. Cancer Res. 2, 676&#x2013;690 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23226614</ArticleId><ArticleId IdType="pmc">3512181</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasicchio, M. et al. SARS-CoV-2 viral replication persists in the human lung for several weeks after symptom onset. Am. J. Respir. Crit. Care Med. 209, 840&#x2013;851 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38226855</ArticleId><ArticleId IdType="pmc">10995573</ArticleId><ArticleId IdType="doi">10.1164/rccm.202308-1438OC</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein, S. R. et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612, 758&#x2013;763 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36517603</ArticleId><ArticleId IdType="pmc">9749650</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkai, I. et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat. Commun. 13, 1745 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35365631</ArticleId><ArticleId IdType="pmc">8975902</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-29440-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrich, F., Mertz, K. D., Glatzel, M., Beer, M. &amp; Krasemann, S. Using autopsies to dissect COVID-19 pathogenesis. Nat. Microbiol. 8, 1986&#x2013;1994 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37798476</ArticleId><ArticleId IdType="doi">10.1038/s41564-023-01488-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimmel, L. et al. Endothelial cells are not productively infected by SARS-CoV-2. Clin. Transl. Immunol. 10, e1350 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1350</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, W. et al. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect. Dis. 24, 845&#x2013;855 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38663423</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(24)00171-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso, M. J. et al. Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection. Sci. Transl. Med. 16, eadk3295 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38959327</ArticleId><ArticleId IdType="pmc">11337933</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.adk3295</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison, A. G., Lin, T. &amp; Wang, P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 41, 1100&#x2013;1115 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33132005</ArticleId><ArticleId IdType="pmc">7556779</ArticleId><ArticleId IdType="doi">10.1016/j.it.2020.10.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory, D. A. et al. Genetic diversity and evolutionary convergence of cryptic SARS-CoV-2 lineages detected via wastewater sequencing. PLoS Pathog. 18, e1010636 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36240259</ArticleId><ArticleId IdType="pmc">9604950</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1010636</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafer, M. M. et al. Tracing the origin of SARS-CoV-2 Omicron-like spike sequences detected in an urban sewershed: a targeted, longitudinal surveillance study of a cryptic wastewater lineage. Lancet Microbe 5, e335&#x2013;e344 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38484748</ArticleId><ArticleId IdType="pmc">11049544</ArticleId><ArticleId IdType="doi">10.1016/S2666-5247(23)00372-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth, D. S. et al. Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater. Nat. Commun. 13, 635 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35115523</ArticleId><ArticleId IdType="pmc">8813986</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-28246-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Q. et al. Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children. Nat. Immunol. 24, 186&#x2013;199 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36536106</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01367-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka, J., Jansari, V., Hornig, M. &amp; Iwasaki, A. Unexplained post-acute infection syndromes. Nat. Med. 28, 911&#x2013;923 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn, K. L. et al. Comparison of medical and mental health sequelae following hospitalization for COVID-19, influenza, and sepsis. JAMA Intern. Med. 183, 806&#x2013;817 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37338892</ArticleId><ArticleId IdType="pmc">10282961</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2023.2228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley, M. K. et al. Intractable COVID-19 and prolonged SARS-CoV-2 replication in a CAR-T-cell therapy recipient: a case study. Clin. Infect. Dis. 73, e815&#x2013;e821 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33507235</ArticleId><ArticleId IdType="pmc">7929077</ArticleId><ArticleId IdType="doi">10.1093/cid/ciab072</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong, T. T. et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series. eBioMedicine 67, 103355 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33915337</ArticleId><ArticleId IdType="pmc">8072072</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103355</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcri, C. et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient &#x2014; a case study. Open. Forum Infect. Dis. 8, ofab217 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34796242</ArticleId><ArticleId IdType="pmc">8135455</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofab217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi, R. T., Castle, A. C., de Oliveira, T. &amp; Lessells, R. J. Case 40-2023: a 70-year-old woman with cough and shortness of breath. N. Engl. J. Med. 389, 2468&#x2013;2476 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38157503</ArticleId><ArticleId IdType="doi">10.1056/NEJMcpc2300910</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi, D. et al. Severe acute respiratory syndrome coronavirus 2 evolution and escape from combination monoclonal antibody treatment in a person with HIV. Open. Forum Infect. Dis. 10, ofad054 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36820315</ArticleId><ArticleId IdType="pmc">9938522</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad054</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters, J. L. et al. Prolonged severe acute respiratory syndrome coronavirus 2 Delta variant shedding in a patient with AIDS: case report and review of the literature. Open. Forum Infect. Dis. 9, ofac479 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36193230</ArticleId><ArticleId IdType="pmc">9494428</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofac479</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell, A. C. et al. Generation of novel severe acute respiratory syndrome coronavirus 2 variants on the B.1.1.7 lineage in 3 patients with advanced human immunodeficiency virus-1 disease. Clin. Infect. Dis. 75, 2016&#x2013;2018 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35616095</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac409</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary, M. C., Crain, C. R., Qiu, X., Hanage, W. &amp; Li, J. Z. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequence characteristics of coronavirus disease 2019 (COVID-19) persistence and reinfection. Clin. Infect. Dis. 74, 237&#x2013;245 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">8135388</ArticleId><ArticleId IdType="doi">10.1093/cid/ciab380</ArticleId></ArticleIdList></Reference><Reference><Citation>Turbett, S. E. et al. Distinguishing SARS-CoV-2 persistence and reinfection: a retrospective cohort study. Clin. Infect. Dis. 76, 850&#x2013;860 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">9619827</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac830</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim, F. et al. HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. eLife 10, e67397 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34608862</ArticleId><ArticleId IdType="pmc">8676326</ArticleId><ArticleId IdType="doi">10.7554/eLife.67397</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigang, S. et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat. Commun. 12, 6405 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34737266</ArticleId><ArticleId IdType="pmc">8568958</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-26602-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko, S. H. et al. Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection. Nat. Commun. 15, 7240 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39174553</ArticleId><ArticleId IdType="pmc">11341811</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-51539-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, C. Y. et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 12, 62&#x2013;73 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34753749</ArticleId><ArticleId IdType="doi">10.1158/2159-8290.CD-21-1033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafari, M. et al. Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature 626, 1094&#x2013;1101 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38383783</ArticleId><ArticleId IdType="pmc">10901734</ArticleId><ArticleId IdType="doi">10.1038/s41586-024-07029-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Harari, S., Miller, D., Fleishon, S., Burstein, D. &amp; Stern, A. Using big sequencing data to identify chronic SARS-coronavirus-2 infections. Nat. Commun. 15, 648 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38245511</ArticleId><ArticleId IdType="pmc">10799923</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-44803-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway, M. J. et al. Chronic shedding of a SARS-CoV-2 Alpha variant in wastewater. BMC Genomics 25, 59 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38218804</ArticleId><ArticleId IdType="pmc">10787452</ArticleId><ArticleId IdType="doi">10.1186/s12864-024-09977-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Lythgoe, K. A. et al. SARS-CoV-2 within-host diversity and transmission. Science 372, eabg0821 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33688063</ArticleId><ArticleId IdType="pmc">8128293</ArticleId><ArticleId IdType="doi">10.1126/science.abg0821</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendall, E. E. et al. Rapid transmission and tight bottlenecks constrain the evolution of highly transmissible SARS-CoV-2 variants. Nat. Commun. 14, 272 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36650162</ArticleId><ArticleId IdType="pmc">9844183</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-36001-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair, P., Zhao, L., Beggs, C. B. &amp; Illingworth, C. J. R. The airborne transmission of viruses causes tight transmission bottlenecks. Nat. Commun. 15, 3540 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38670957</ArticleId><ArticleId IdType="pmc">11053022</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-47923-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun, K. M. et al. Acute SARS-CoV-2 infections harbor limited within-host diversity and transmit via tight transmission bottlenecks. PLoS Pathog. 17, e1009849 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34424945</ArticleId><ArticleId IdType="pmc">8412271</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1009849</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyano, A., Lustig, G., Rodel, H. E., Antal, T. &amp; Sigal, A. Interference with HIV infection of the first cell is essential for viral clearance at sub-optimal levels of drug inhibition. PLoS Comput. Biol. 16, e1007482 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32017770</ArticleId><ArticleId IdType="pmc">7039526</ArticleId><ArticleId IdType="doi">10.1371/journal.pcbi.1007482</ArticleId></ArticleIdList></Reference><Reference><Citation>Neher, R. A. Contributions of adaptation and purifying selection to SARS-CoV-2 evolution. Virus Evol. 8, veac113 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">37593203</ArticleId><ArticleId IdType="pmc">10431346</ArticleId><ArticleId IdType="doi">10.1093/ve/veac113</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;versti, S., Gaul, E., Jensen, B.-E. O. &amp; K&#xfc;hnert, D. Phylogenetic meta-analysis of chronic SARS-CoV-2 infections in immunocompromised patients shows no evidence of elevated evolutionary rates. Preprint at bioRxiv https://doi.org/10.1101/2023.11.01.565087 (2023).</Citation></Reference><Reference><Citation>Morris, D. H. et al. Asynchrony between virus diversity and antibody selection limits influenza virus evolution. eLife 9, e62105 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33174838</ArticleId><ArticleId IdType="pmc">7748417</ArticleId><ArticleId IdType="doi">10.7554/eLife.62105</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162&#x2013;177 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36653446</ArticleId><ArticleId IdType="pmc">9847462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, J. et al. Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway. Cell Rep. 38, 110344 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35093235</ArticleId><ArticleId IdType="pmc">8768428</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.110344</ArticleId></ArticleIdList></Reference><Reference><Citation>Theys, K. et al. The impact of HIV-1 within-host evolution on transmission dynamics. Curr. Opin. Virol. 28, 92&#x2013;101 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29275182</ArticleId><ArticleId IdType="doi">10.1016/j.coviro.2017.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lythgoe, K. A., Gardner, A., Pybus, O. G. &amp; Grove, J. Short-sighted virus evolution and a germline hypothesis for chronic viral infections. Trends Microbiol. 25, 336&#x2013;348 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28377208</ArticleId><ArticleId IdType="pmc">5405858</ArticleId><ArticleId IdType="doi">10.1016/j.tim.2017.03.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuschl, A. K. et al. Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants. Nat. Microbiol. 9, 451&#x2013;463 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38228858</ArticleId><ArticleId IdType="pmc">10847042</ArticleId><ArticleId IdType="doi">10.1038/s41564-023-01588-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorne, L. G. et al. Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature 602, 487&#x2013;495 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34942634</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04352-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchrieser, J. et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 39, e106267 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33051876</ArticleId><ArticleId IdType="pmc">7646020</ArticleId><ArticleId IdType="doi">10.15252/embj.2020106267</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajah, M. M. et al. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced spike-mediated syncytia formation. EMBO J. 40, e108944 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34601723</ArticleId><ArticleId IdType="pmc">8646911</ArticleId><ArticleId IdType="doi">10.15252/embj.2021108944</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaumdally, S. et al. Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants. Nat. Commun. 15, 2003 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38443359</ArticleId><ArticleId IdType="pmc">10914788</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-45400-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Earnest, R. et al. Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. Cell Rep. Med. 3, 100583 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35480627</ArticleId><ArticleId IdType="pmc">8913280</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2022.100583</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart, W. S. et al. Generation time of the Alpha and Delta SARS-CoV-2 variants: an epidemiological analysis. Lancet Infect. Dis. 22, 603&#x2013;610 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35176230</ArticleId><ArticleId IdType="pmc">8843191</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00001-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyngse, F. P. et al. Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load. Nat. Commun. 12, 7251 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34903718</ArticleId><ArticleId IdType="pmc">8669007</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-27202-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114&#x2013;119 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34488225</ArticleId><ArticleId IdType="pmc">8566220</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03944-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654&#x2013;656 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35016196</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04387-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348&#x2013;2361.e6 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33730597</ArticleId><ArticleId IdType="pmc">7901269</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.02.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467&#x2013;484.e15 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35081335</ArticleId><ArticleId IdType="pmc">8723827</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.12.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann, N. P. et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 387, 86&#x2013;88 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35731894</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2206576</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, K. et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature 607, 356&#x2013;359 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35523247</ArticleId><ArticleId IdType="pmc">9279144</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04830-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, K. et al. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat. Commun. 13, 4686 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35948557</ArticleId><ArticleId IdType="pmc">9364294</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-32396-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi, S. A. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV 8, e568&#x2013;e580 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34416193</ArticleId><ArticleId IdType="pmc">8372504</ArticleId><ArticleId IdType="doi">10.1016/S2352-3018(21)00157-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657&#x2013;663 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35016194</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, P. et al. Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization. Cell Host Microbe 29, 747&#x2013;751.e4 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33887205</ArticleId><ArticleId IdType="pmc">8053237</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2021.04.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies. Cell 184, 2384&#x2013;2393.e12 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33794143</ArticleId><ArticleId IdType="pmc">7980144</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.03.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Goga, A. et al. Breakthrough SARS-CoV-2 infections during periods of Delta and Omicron predominance, South Africa. Lancet 400, 269&#x2013;271 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35809579</ArticleId><ArticleId IdType="pmc">9259009</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)01190-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney, A. J. et al. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. PLoS Pathog. 18, e1010248 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35134084</ArticleId><ArticleId IdType="pmc">8856557</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1010248</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917&#x2013;924 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33772244</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01318-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, C. W. et al. SARS-CoV-2 Omicron variant emerged under immune selection. Nat. Microbiol. 7, 1756&#x2013;1761 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36195753</ArticleId><ArticleId IdType="doi">10.1038/s41564-022-01246-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill, V. et al. The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. Virus Evol. 8, veac080 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36533153</ArticleId><ArticleId IdType="pmc">9752794</ArticleId><ArticleId IdType="doi">10.1093/ve/veac080</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut, A. et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563 (2020).</Citation></Reference><Reference><Citation>Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature 602, 294&#x2013;299 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34818667</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04245-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, L.-Y. R. et al. Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature 605, 146&#x2013;151 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35314834</ArticleId><ArticleId IdType="pmc">9783543</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04630-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng, B. et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 35, 109292 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34166617</ArticleId><ArticleId IdType="pmc">8185188</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bills, C. J. et al. Mutations in SARS-CoV-2 variant nsp6 enhance type-I interferon antagonism. Emerg. Microbes Infect. 12, 2209208 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37114433</ArticleId><ArticleId IdType="pmc">10184609</ArticleId><ArticleId IdType="doi">10.1080/22221751.2023.2209208</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438&#x2013;443 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33690265</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03402-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142&#x2013;146 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33780970</ArticleId><ArticleId IdType="pmc">9867906</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03471-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Escalera, A. et al. Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. Cell Host Microbe 30, 373&#x2013;387.e7 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35150638</ArticleId><ArticleId IdType="pmc">8776496</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2022.01.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27, 622&#x2013;625 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33654292</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01285-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra, S. et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2, e283&#x2013;e284 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33846703</ArticleId><ArticleId IdType="pmc">8026167</ArticleId><ArticleId IdType="doi">10.1016/S2666-5247(21)00068-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616&#x2013;622 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33567448</ArticleId><ArticleId IdType="pmc">8503938</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03324-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409&#x2013;424 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34075212</ArticleId><ArticleId IdType="pmc">8167834</ArticleId><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleynhans, J. et al. SARS-CoV-2 seroprevalence after third wave of infections, South Africa. Emerg. Infect. Dis. 28, 1055&#x2013;1058 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35320701</ArticleId><ArticleId IdType="pmc">9045427</ArticleId><ArticleId IdType="doi">10.3201/eid2805.220278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, K. et al. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. Nat. Commun. 14, 246 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36646700</ArticleId><ArticleId IdType="pmc">9842214</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-35652-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyngse, F. P. et al. Household transmission of the SARS-CoV-2 Omicron variant in Denmark. Nat. Commun. 13, 5573 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36151099</ArticleId><ArticleId IdType="pmc">9508106</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-33328-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature 603, 679&#x2013;686 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35042229</ArticleId><ArticleId IdType="pmc">8942855</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04411-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 Omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234&#x2013;236 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34942101</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)02844-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457&#x2013;466.e4 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34995482</ArticleId><ArticleId IdType="pmc">8733787</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Servellita, V. et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell 185, 1539&#x2013;1548.e5 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35429436</ArticleId><ArticleId IdType="pmc">8930394</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.03.019</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 28, 490&#x2013;495 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35046573</ArticleId><ArticleId IdType="pmc">8767531</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01678-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Riou, C. et al. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants. PLoS Glob. Public. Health 4, e0002703 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38603677</ArticleId><ArticleId IdType="pmc">11008839</ArticleId><ArticleId IdType="doi">10.1371/journal.pgph.0002703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann, C. et al. Breakthrough infections with SARS-CoV-2 Omicron despite mRNA vaccine booster dose. Lancet 399, 625&#x2013;626 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35063123</ArticleId><ArticleId IdType="pmc">8765759</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)00090-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulliam, J. R. C. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 376, eabn4947 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35289632</ArticleId><ArticleId IdType="doi">10.1126/science.abn4947</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson, S. A. J. et al. Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus Evol. 8, veac050 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35996593</ArticleId><ArticleId IdType="pmc">9384748</ArticleId><ArticleId IdType="doi">10.1093/ve/veac050</ArticleId></ArticleIdList></Reference><Reference><Citation>Monrad, I. et al. Persistent severe acute respiratory syndrome coronavirus 2 infection in immunocompromised host displaying treatment induced viral evolution. Open. Forum Infect. Dis. 8, ofab295 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34258320</ArticleId><ArticleId IdType="pmc">8244814</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofab295</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnleitner, S. T. et al. Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. Nat. Commun. 13, 2560 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35538074</ArticleId><ArticleId IdType="pmc">9090742</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-30163-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep. 39, 110829 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35550680</ArticleId><ArticleId IdType="pmc">9050581</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.110829</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, A. et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602, 300&#x2013;306 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34823256</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04266-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, K. et al. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant. Nat. Commun. 14, 8078 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38057313</ArticleId><ArticleId IdType="pmc">10700484</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-43703-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Harari, S. et al. Drivers of adaptive evolution during chronic SARS-CoV-2 infections. Nat. Med. 28, 1501&#x2013;1508 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35725921</ArticleId><ArticleId IdType="pmc">9307477</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01882-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkoff, J. M. &amp; tenOever, B. Innate immune evasion strategies of SARS-CoV-2. Nat. Rev. Microbiol. 21, 178&#x2013;194 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36631691</ArticleId><ArticleId IdType="pmc">9838430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall, R. et al. SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export. PLoS Pathog. 18, e1010349 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36007063</ArticleId><ArticleId IdType="pmc">9451085</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1010349</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657&#x2013;662 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32726803</ArticleId><ArticleId IdType="pmc">7116779</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2601-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris, E. CDC tracking BA.2.87.1, new Omicron subvariant with potential to evade immunity. JAMA 331, 907 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38416485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado, N. et al. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86. Vaccine 41, 6904&#x2013;6909 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37872011</ArticleId><ArticleId IdType="pmc">10842519</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2023.10.051</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesamari, R. et al. Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant. Cell Host Microbe 32, 162&#x2013;169.e3 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38211583</ArticleId><ArticleId IdType="pmc">10901529</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2023.12.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheward, D. J. et al. Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses. Lancet Infect. Dis. 23, e462&#x2013;e463 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37776877</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00588-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Uriu, K. et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect. Dis. 23, e460&#x2013;e461 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37734391</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00575-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature 624, 639&#x2013;644 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37871613</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06750-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, S. et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect. Dis. 23, e457&#x2013;e459 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37738994</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00573-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat. Commun. 15, 2254 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38480689</ArticleId><ArticleId IdType="pmc">10938001</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-46490-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, S. et al. Fast evolution of SARS-CoV-2 BA. 2.86 to JN. 1 under heavy immune pressure. Lancet Infect. Dis. 24, e70&#x2013;e72 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38109919</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00744-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally, H. et al. The evolving SARS-CoV-2 epidemic in Africa: insights from rapidly expanding genomic surveillance. Science 378, eabq5358 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36108049</ArticleId><ArticleId IdType="doi">10.1126/science.abq5358</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers, M. M. &amp; Haagmans, B. L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 20, 270&#x2013;284 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35354968</ArticleId><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz, E. A. &amp; Li, Y. Review: the landscape of antiviral therapy for COVID-19 in the era of widespread population immunity and Omicron-lineage viruses. Clin. Infect. Dis. 78, 908&#x2013;917 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37949817</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad685</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz, E. A., Scott, J., Richterman, A., Male, V. &amp; Cevik, M. Clinical course and management of COVID-19 in the era of widespread population immunity. Nat. Rev. Microbiol. 22, 75&#x2013;88 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38114838</ArticleId><ArticleId IdType="doi">10.1038/s41579-023-01001-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran, E. et al. Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. Lancet Infect. Dis. 21, 1345&#x2013;1347 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34411531</ArticleId><ArticleId IdType="pmc">8367192</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00464-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Breeden, M. et al. Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended nirmatrelvir/ritonavir: case series. Open Forum Infect. Dis. 10, ofad189 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37089775</ArticleId><ArticleId IdType="pmc">10114524</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad189</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell, L. B. et al. A multinational case series describing successful treatment of persistent severe acute respiratory syndrome coronavirus 2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir/ritonavir. Open. Forum Infect. Dis. 11, ofad612 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38269048</ArticleId><ArticleId IdType="pmc">10807981</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. &amp; Brosh-Nissimov, T. Nirmatrelvir resistance &#x2014; de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure &#x2014; a case report. Clin. Infect. Dis. 78, 352&#x2013;355 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad494</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow, O., Vesterbacka, J., Tovatt, T. &amp; Nowak, P. Successful combination treatment for persistent severe acute respiratory syndrome coronavirus 2 infection. Clin. Infect. Dis. 76, 1864&#x2013;1865 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36782402</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad085</ArticleId></ArticleIdList></Reference><Reference><Citation>Huygens, S. et al. Clinical and virological outcome of monoclonal antibody therapies across severe acute respiratory syndrome coronavirus 2 variants in 245 immunocompromised patients: a multicenter prospective cohort study. Clin. Infect. Dis. 78, 1514&#x2013;1521 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38445721</ArticleId><ArticleId IdType="pmc">11175671</ArticleId><ArticleId IdType="doi">10.1093/cid/ciae026</ArticleId></ArticleIdList></Reference><Reference><Citation>Huygens, S. et al. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients. J. Antimicrob. Chemother. 78, 1644&#x2013;1648 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37248664</ArticleId><ArticleId IdType="pmc">10320105</ArticleId><ArticleId IdType="doi">10.1093/jac/dkad144</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikulska, M. et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin. Infect. Dis. 77, 280&#x2013;286 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36976301</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad181</ArticleId></ArticleIdList></Reference><Reference><Citation>Trottier, C. A. et al. Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host. Clin. Infect. Dis. 76, 923&#x2013;925 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac847</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, S., Parker, J., Smits, S., Underwood, J. &amp; Dolwani, S. Persistent viral shedding of SARS-CoV-2 in faeces &#x2014; a rapid review. Colorectal Dis. 22, 611&#x2013;620 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32418307</ArticleId><ArticleId IdType="pmc">7276890</ArticleId><ArticleId IdType="doi">10.1111/codi.15138</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. &amp; Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133&#x2013;146 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36639608</ArticleId><ArticleId IdType="pmc">9839201</ArticleId><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso, D. et al. Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies. Lancet Microbe 4, e745&#x2013;e756 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37385286</ArticleId><ArticleId IdType="doi">10.1016/S2666-5247(23)00115-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Subissi, L. et al. An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution. Nat. Med. 30, 2400&#x2013;2403 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38720002</ArticleId><ArticleId IdType="doi">10.1038/s41591-024-02949-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker, M. et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat. Commun. 13, 6856 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36369151</ArticleId><ArticleId IdType="pmc">9651890</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-34244-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat, W. et al. Clinical severity of COVID-19 in patients admitted to hospital during the Omicron wave in South Africa: a retrospective observational study. Lancet Glob. Health 10, e961&#x2013;e969 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35597249</ArticleId><ArticleId IdType="pmc">9116895</ArticleId><ArticleId IdType="doi">10.1016/S2214-109X(22)00114-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706&#x2013;714 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35104837</ArticleId><ArticleId IdType="pmc">8942856</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J. M. et al. Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin. eLife 8, e49324 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31452511</ArticleId><ArticleId IdType="pmc">6711711</ArticleId><ArticleId IdType="doi">10.7554/eLife.49324</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh, F. C. et al. Age-dependent heterogeneity in the antigenic effects of mutations to influenza hemagglutinin. Cell Host Microbe 32, 1397&#x2013;1411.e11 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39032493</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2024.06.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, C.-Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950&#x2013;960 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38749479</ArticleId><ArticleId IdType="doi">10.1038/s41586-024-07539-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksamentov, I., Roemer, C., Hodcroft, E. B. &amp; Neher, R. A. Nextclade: clade assignment, mutation calling and quality control for viral genomes. J. Open. Source Softw. 6, 3773 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.03773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, H. &amp; Robertson, E. S. Epstein&#x2013;Barr virus history and pathogenesis. Viruses 15, 714 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36992423</ArticleId><ArticleId IdType="pmc">10056551</ArticleId><ArticleId IdType="doi">10.3390/v15030714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigal, A. &amp; Baltimore, D. As good as it gets? The problem of HIV persistence despite antiretroviral drugs. Cell Host Microbe 12, 132&#x2013;138 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22901535</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2012.07.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Churchill, M. J., Deeks, S. G., Margolis, D. M., Siliciano, R. F. &amp; Swanstrom, R. HIV reservoirs: what, where and how to target them. Nat. Rev. Microbiol. 14, 55&#x2013;60 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26616417</ArticleId><ArticleId IdType="doi">10.1038/nrmicro.2015.5</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansky, L. M. &amp; Temin, H. M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69, 5087&#x2013;5094 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7541846</ArticleId><ArticleId IdType="pmc">189326</ArticleId><ArticleId IdType="doi">10.1128/jvi.69.8.5087-5094.1995</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142&#x2013;158 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35962033</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00753-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, J. S. &amp; Bjorkman, P. J. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 6, e1000908 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20523901</ArticleId><ArticleId IdType="pmc">2877745</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1000908</ArticleId></ArticleIdList></Reference><Reference><Citation>Abela, I. A. et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 8, e1002634 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22496655</ArticleId><ArticleId IdType="pmc">3320602</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1002634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigal, A. et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477, 95&#x2013;98 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21849975</ArticleId><ArticleId IdType="doi">10.1038/nature10347</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson, L. et al. Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by reducing cell death. eLife 7, e30134 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29555018</ArticleId><ArticleId IdType="pmc">5896883</ArticleId><ArticleId IdType="doi">10.7554/eLife.30134</ArticleId></ArticleIdList></Reference><Reference><Citation>Boull&#xe9;, M. et al. HIV cell-to-cell spread results in earlier onset of viral gene expression by multiple infections per cell. PLoS Pathog. 12, e1005964 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27812216</ArticleId><ArticleId IdType="pmc">5094736</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1005964</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Ria&#xf1;o, A. et al. Long-term retention of antigens in germinal centers is controlled by the spatial organization of the follicular dendritic cell network. Nat. Immunol. 24, 1281&#x2013;1294 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37443283</ArticleId><ArticleId IdType="pmc">7614842</ArticleId><ArticleId IdType="doi">10.1038/s41590-023-01559-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Heesters, B. A. et al. Follicular dendritic cells retain infectious HIV in cycling endosomes. PLoS Pathog. 11, e1005285 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26623655</ArticleId><ArticleId IdType="pmc">4666623</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1005285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig, G. et al. T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy. PLoS Pathog. 17, e1009871 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34555123</ArticleId><ArticleId IdType="pmc">8509856</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1009871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kincer, L. P. et al. Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus. Nat. Microbiol. 8, 260&#x2013;271 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36717718</ArticleId><ArticleId IdType="pmc">10201410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob, S. T. et al. Ebola virus disease. Nat. Rev. Dis. Prim. 6, 13 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32080199</ArticleId><ArticleId IdType="doi">10.1038/s41572-020-0147-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J. et al. Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. Sci. Transl. Med. 14, eabi5229 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35138912</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abi5229</ArticleId></ArticleIdList></Reference><Reference><Citation>Worwa, G. et al. Persistent intraocular Ebola virus RNA is associated with severe uveitis in a convalescent rhesus monkey. Commun. Biol. 5, 1204 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36352100</ArticleId><ArticleId IdType="pmc">9644391</ArticleId><ArticleId IdType="doi">10.1038/s42003-022-04158-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Lion, T. Adenovirus persistence, reactivation, and clinical management. FEBS Lett. 593, 3571&#x2013;3582 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31411731</ArticleId><ArticleId IdType="doi">10.1002/1873-3468.13576</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue, K. S., Moncla, L. H., Bedford, T. &amp; Bloom, J. D. Within-host evolution of human influenza virus. Trends Microbiol. 26, 781&#x2013;793 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29534854</ArticleId><ArticleId IdType="pmc">6097882</ArticleId><ArticleId IdType="doi">10.1016/j.tim.2018.02.007</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn, P., Carrello, A., Cole, C., Baker, D. &amp; Hampson, A. Antigenic drift of influenza A (H3N2) virus in a persistently infected immunocompromised host is similar to that occurring in the community. Clin. Infect. Dis. 29, 456&#x2013;458 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10476769</ArticleId><ArticleId IdType="doi">10.1086/520243</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers, M. B. et al. Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection. mBio 6, e02464&#x2013;e02514 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25852163</ArticleId><ArticleId IdType="pmc">4453542</ArticleId><ArticleId IdType="doi">10.1128/mBio.02464-14</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock, D. M., Gubareva, L. V. &amp; Zuccotti, G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med. 348, 867&#x2013;868 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12606750</ArticleId><ArticleId IdType="doi">10.1056/NEJM200302273480923</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue, K. S. et al. Parallel evolution of influenza across multiple spatiotemporal scales. eLife 6, e26875 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28653624</ArticleId><ArticleId IdType="pmc">5487208</ArticleId><ArticleId IdType="doi">10.7554/eLife.26875</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabatabai, J. et al. Parainfluenza virus infections in patients with hematological malignancies or stem cell transplantation: analysis of clinical characteristics, nosocomial transmission and viral shedding. PLoS ONE 17, e0271756 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35905071</ArticleId><ArticleId IdType="pmc">9337657</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0271756</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann, I. et al. In vivo persistence of human rhinoviruses in immunosuppressed patients. PLoS ONE 12, e0170774 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28151988</ArticleId><ArticleId IdType="pmc">5289482</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0170774</ArticleId></ArticleIdList></Reference><Reference><Citation>Milano, F. et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood 115, 2088&#x2013;2094 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20042728</ArticleId><ArticleId IdType="pmc">2837322</ArticleId><ArticleId IdType="doi">10.1182/blood-2009-09-244152</ArticleId></ArticleIdList></Reference><Reference><Citation>Hierholzer, J. C. Adenoviruses in the immunocompromised host. Clin. Microbiol. Rev. 5, 262&#x2013;274 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1323383</ArticleId><ArticleId IdType="pmc">358244</ArticleId><ArticleId IdType="doi">10.1128/CMR.5.3.262</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez, S. R., Robinson, C. C. &amp; Holmes, K. V. Detection of four human coronaviruses in respiratory infections in children: a one-year study in Colorado. J. Med. Virol. 81, 1597&#x2013;1604 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19626607</ArticleId><ArticleId IdType="pmc">2879166</ArticleId><ArticleId IdType="doi">10.1002/jmv.21541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, K. H. et al. Persistent dengue infection in an immunosuppressed patient reveals the roles of humoral and cellular immune responses in virus clearance. Cell Host Microbe 26, 601&#x2013;605.e3 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31676304</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2019.10.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado, C. M. et al. Zika and chikungunya virus infections in hematopoietic stem cell transplant recipients and oncohematological patients. Blood Adv. 1, 624&#x2013;627 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29296705</ArticleId><ArticleId IdType="pmc">5728351</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2016003285</ArticleId></ArticleIdList></Reference><Reference><Citation>Haessler, S. &amp; Granowitz, E. V. Norovirus gastroenteritis in immunocompromised patients. N. Engl. J. Med. 368, 971 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23465122</ArticleId><ArticleId IdType="doi">10.1056/NEJMc1301022</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyer, A. et al. Intrahost norovirus evolution in chronic infection over 5&#x2009;years of shedding in a kidney transplant recipient. Front. Microbiol. 9, 371 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29552005</ArticleId><ArticleId IdType="pmc">5840165</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2018.00371</ArticleId></ArticleIdList></Reference><Reference><Citation>Malka, M. S. et al. A prolonged case of severe mpox as an opportunistic infection in advanced AIDS. Cureus 16, e59947 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38854169</ArticleId><ArticleId IdType="pmc">11161852</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Shea, J. et al. Prolonged mpox disease in people with advanced HIV: characterization of mpox skin lesions. J. Infect. Dis. 229, S243&#x2013;S248 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">10965209</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad532</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinnetti, C. et al. mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications. Lancet Infect. Dis. 24, e127&#x2013;e135 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37778364</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00482-6</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>